Background For treating multidrug-resistant tuberculosis (MDR TB), the World Health
Organization (WHO) recommends a regimen of at least four second-line drugs that are likely …

Background. Resistance to second-line drugs develops during treatment of multidrug-
resistant (MDR) tuberculosis, but the impact on treatment outcome has not been determined …

Sputum cultures are an important tool in monitoring the response to tuberculosis treatment,
especially in multidrug-resistant tuberculosis. There has, however, been little study of the …

Background. Evidence is sparse regarding the optimal construction of regimens to treat
multidrug-resistant (MDR) tuberculosis disease due to strains of Mycobacterium tuberculosis …

Background Understanding the impact of drug exposure and susceptibility on treatment
response of multidrug-resistant tuberculosis (MDR-TB) will help to optimise treatment. This …

Rationale A better understanding of the composition of optimal treatment regimens for
multidrug-resistant tuberculosis (MDR-TB) is essential for expanding universal access to …

We assessed the effectiveness and safety of standardised, shorter multidrug-resistant
tuberculosis (MDR-TB) regimens by pooling data from observational studies. Published …

SETTING: Globally it is estimated that 273000 new cases of multidrug-resistant tuberculosis
(MDR-TB, resistance to isoniazid and rifampicin) occurred in 2000. To address MDR-TB …

BACKGROUND: Excellent treatment outcomes have recently been reported for patients with
multi/extensively drug-resistant tuberculosis (M/XDR-TB) in settings where optimal …

BACKGROUND: The treatment of multidrug-resistant tuberculosis (MDR-TB) is currently
based upon expert opinion and findings from case series, rather than upon randomised …